MaxCyte Expects Core Revenue of Up to $29.6 Million for 2025
I'm PortAI, I can summarize articles.
MaxCyte Inc. anticipates core revenue of $29.5 million to $29.6 million for 2025, with fourth-quarter revenue expected between $6.6 million and $6.7 million. SPL program-related revenue is projected at $0.4 million to $0.6 million for Q4 and $3.3 million to $3.5 million for the full year. The company aims to return to revenue growth in H2 2026, ending 2025 with approximately $155.6 million in cash and investments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments